Shanghai-based biopharmaceutical company focused on developing and commercializing improved-formulation medicines and other innovative drugs
Shanghai-based biopharmaceutical company focused on developing and commercializing improved-formulation medicines and other innovative drugs. It adapts medicines to address unmet clinical needs through new dosage forms, indications, and administration regimens, pursuing US FDA 505(b)(2) and China NMPA Class 2 drug approval pathways. Research areas include infantile hemangioma, hepatitis B, and drug delivery for special populations.